Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CDMO NASDAQ:CMRX NASDAQ:LRMR NASDAQ:OCS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCDMOAvid Bioservices$12.50+0.1%$12.50$7.49▼$12.51$799.18M1.391.46 million shs3.07 million shsCMRXChimerix$8.54$8.54$0.75▼$8.55$801.09M-0.172.81 million shsN/ALRMRLarimar Therapeutics$3.44-1.3%$2.55$1.61▼$11.20$220.58M0.86840,155 shs370,776 shsOCSOculis$18.21-1.0%$18.97$10.79▼$23.08$795.09M0.2945,231 shs14,318 shs7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCDMOAvid Bioservices0.00%0.00%0.00%0.00%+69.08%CMRXChimerix0.00%0.00%0.00%+0.23%+918.36%LRMRLarimar Therapeutics+0.58%+10.83%+19.59%+92.27%-61.99%OCSOculis-0.16%-2.93%-7.02%+9.85%+64.29%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCDMOAvid Bioservices0.7429 of 5 stars1.00.00.04.50.01.70.6CMRXChimerix0.6709 of 5 stars1.00.00.04.10.01.70.6LRMRLarimar Therapeutics1.5683 of 5 stars3.61.00.00.01.11.70.0OCSOculis1.807 of 5 stars3.53.00.00.00.60.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCDMOAvid Bioservices 2.00Hold$12.25-1.96% DownsideCMRXChimerix 2.00Hold$8.53-0.08% DownsideLRMRLarimar Therapeutics 3.11Buy$18.50449.94% UpsideOCSOculis 3.00Buy$35.3392.12% UpsideCurrent Analyst Ratings BreakdownLatest LRMR, OCS, CMRX, and CDMO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/24/2025LRMRLarimar TherapeuticsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy6/24/2025LRMRLarimar TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$17.00 ➝ $15.006/24/2025LRMRLarimar TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$26.005/9/2025OCSOculisChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$28.00 ➝ $33.004/17/2025OCSOculisHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$29.00 ➝ $32.004/17/2025OCSOculisChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$28.00 ➝ $28.00(Data available from 7/11/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCDMOAvid Bioservices$139.91M5.71$0.15 per share80.92$3.02 per share4.14CMRXChimerix$212K3,778.71N/AN/A$2.17 per share3.94LRMRLarimar TherapeuticsN/AN/AN/AN/A$2.69 per shareN/AOCSOculisN/AN/AN/AN/A$1.91 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCDMOAvid Bioservices-$140.75M-$2.39N/AN/AN/A-101.07%-33.18%-8.45%9/8/2025 (Estimated)CMRXChimerix-$82.10M-$0.99N/AN/AN/AN/A-50.78%-44.94%8/11/2025 (Estimated)LRMRLarimar Therapeutics-$80.60M-$1.49N/AN/AN/AN/A-52.48%-46.08%8/6/2025 (Estimated)OCSOculis-$97.43M-$2.64N/AN/AN/A-13,788.70%-92.95%-70.03%8/26/2025 (Estimated)Latest LRMR, OCS, CMRX, and CDMO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/6/2025Q2 2025LRMRLarimar Therapeutics-$0.4877N/AN/AN/AN/AN/A5/8/2025Q1 2025OCSOculis-$0.51-$0.77-$0.26-$0.77$0.22 million$0.32 million4/30/2025Q1 2025LRMRLarimar Therapeutics-$0.42-$0.46-$0.04-$0.46N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCDMOAvid BioservicesN/AN/AN/AN/AN/ACMRXChimerixN/AN/AN/AN/AN/ALRMRLarimar TherapeuticsN/AN/AN/AN/AN/AOCSOculisN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCDMOAvid Bioservices3.581.300.92CMRXChimerixN/A6.336.33LRMRLarimar TherapeuticsN/A7.487.48OCSOculisN/A4.794.79Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCDMOAvid Bioservices97.16%CMRXChimerix45.42%LRMRLarimar Therapeutics91.92%OCSOculis22.30%Insider OwnershipCompanyInsider OwnershipCDMOAvid Bioservices3.05%CMRXChimerix13.10%LRMRLarimar Therapeutics4.50%OCSOculisN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCDMOAvid Bioservices32063.96 million62.01 millionOptionableCMRXChimerix9093.80 million78.15 millionOptionableLRMRLarimar Therapeutics3064.03 million61.15 millionOptionableOCSOculis243.66 millionN/ANot OptionableLRMR, OCS, CMRX, and CDMO HeadlinesRecent News About These CompaniesOculis (NASDAQ:OCS) Stock Price Down 1.1% - What's Next?July 10 at 3:54 AM | marketbeat.comOculis Publishes Notifications of Transactions by Persons Discharging Managerial ResponsibilitiesJuly 9 at 4:05 PM | globenewswire.comOCS - Oculis Holding AG Executives - MorningstarJuly 5, 2025 | morningstar.comMOculis Holding AG (OCS) - Yahoo FinanceJune 28, 2025 | sg.finance.yahoo.comOculis Holding AG (NASDAQ:OCS) Sees Large Increase in Short InterestJune 17, 2025 | marketbeat.comOculis Publishes Results of 2025 Annual General MeetingJune 5, 2025 | globenewswire.comOculis Publishes Results of 2025 Annual General MeetingJune 5, 2025 | globenewswire.comOculis Publishes Notifications of Transactions by Persons Discharging Managerial ResponsibilitiesJune 3, 2025 | globenewswire.comOculis to Participate in Upcoming June Investor ConferencesJune 3, 2025 | markets.businessinsider.comOculis Holding AG Announces Participation in Upcoming Investor Conferences in June 2025June 3, 2025 | quiverquant.comQOculis to Participate in Upcoming June Investor ConferencesJune 3, 2025 | globenewswire.comOculis to Participate in Upcoming June Investor ConferencesJune 3, 2025 | globenewswire.comOculis Holding AG: Oculis Reports Q1 Financial Results and Provides Company UpdateMay 11, 2025 | finanznachrichten.deOculis Publishes Invitation to the Annual General MeetingMay 9, 2025 | globenewswire.comOculis Publishes Invitation to the Annual General MeetingMay 9, 2025 | globenewswire.comOculis posts widening quarterly loss as R&D spend climbsMay 9, 2025 | thepharmaletter.comTOculis Holding AG (OCS) Reports Q1 Loss, Tops Revenue EstimatesMay 8, 2025 | zacks.comOculis Reports Q1 Financial Results and Provides Company UpdateMay 8, 2025 | globenewswire.comOculis Reports Q1 2025 Financial Results and Provides Company UpdateMay 8, 2025 | globenewswire.comEarnings Preview: Oculis Holding AG (OCS) Q1 Earnings Expected to DeclineMay 7, 2025 | zacks.comOculis to Present at Upcoming May Investor ConferencesMay 7, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeLRMR, OCS, CMRX, and CDMO Company DescriptionsAvid Bioservices NASDAQ:CDMO$12.50 +0.02 (+0.12%) Closing price 02/5/2025Extended Trading$12.50 0.00 (0.00%) As of 02/5/2025 04:23 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Avid Bioservices, Inc. operates as a contract development and manufacturing organization for the biotechnology and biopharmaceutical industries in the United States. It provides process development and current good manufacturing practice clinical and commercial manufacturing services of biologics, including clinical and commercial drug substance manufacturing, bulk packaging, release and stability testing, regulatory submission and support, upstream and downstream development and optimization, analytical methods development, cell line development, testing, and characterization services. The company was formerly known as Peregrine Pharmaceuticals, Inc. and changed its name to Avid Bioservices, Inc. in January 2018. Avid Bioservices, Inc. was incorporated in 1981 and is based in Tustin, California.Chimerix NASDAQ:CMRX$8.54 0.00 (0.00%) As of 04/21/2025Chimerix, Inc., a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors. The company also develops ONC212, an imipridone agonist of the orphan G protein-coupled receptors (GPCR) tumor suppressor GPR132, as well as ClpP for oncology indications; and CMX521, a nucleoside analog antiviral drug candidate for the treatment of SARS-CoV-2. It has license agreement with SymBio Pharmaceuticals to develop and commercialize TEMBEXA for human diseases other than orthopoxviruses, including smallpox. Chimerix, Inc. was incorporated in 2000 and is headquartered in Durham, North Carolina.Larimar Therapeutics NASDAQ:LRMR$3.44 -0.05 (-1.29%) As of 02:03 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease. Larimar Therapeutics, Inc. is based in Bala Cynwyd, Pennsylvania.Oculis NASDAQ:OCS$18.21 -0.19 (-1.03%) As of 02:03 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis. The company is based in Zug, Switzerland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Nebius Group: Up 385%, Analysts Say It’s Still a Bargain Broadcom Stock: HSBC Sets $400 Target on AI Growth Potential BigBear.ai: Why a 90% Rally Could Be Just the Start Chipotle: Too Spicy for Smart Money to Resist After Stock Split Plug Power’s 20% Surge Signals New Commercial Growth Era Will Oracle's Cloud and AI Deals Propel It to New Highs? Enovix Shares Hit 6-Month High; Long-Term Highs to Follow Tesla Stock Could Accelerate on New EV Tax Legislation Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
